iShares Biotechnology ETF
803 hedge funds and large institutions have $4.63B invested in iShares Biotechnology ETF in 2025 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 156 increasing their positions, 326 reducing their positions, and 65 closing their positions.
31% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 65
17% more capital invested
Capital invested by funds: $3.94B → $4.63B (+$686M)
6.06% more ownership
Funds ownership: 74.02% → 80.08% (+6.1%)
1% more funds holding
Funds holding: 797 → 803 (+6)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
27% less call options, than puts
Call options by funds: $185M | Put options by funds: $253M
52% less repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 326
Top Buyers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$198M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$61.5M |
| 3 |
Jane Street
New York
|
+$38.2M |
| 4 |
JP Morgan Chase
New York
|
+$31M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$20.5M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$67.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$51.4M |
| 3 |
Citigroup
New York
|
-$48.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$33.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.1M |
IBB Hedge Fund Activity: Q3 2025 in Review
803 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2025, worth a combined $4.63B — up 17% from $3.94B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new IBB positions and 65 closed out — a net gain of 20 holders — while 156 added to existing stakes and 326 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $198M. The largest seller was Morgan Stanley, cutting an estimated $67.4M.
- 803 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2025, up from 797 in Q2 2025.
- Funds reported $4.63B of iShares Biotechnology ETF stock for Q3 2025, up 17% quarter-over-quarter.
- 85 funds opened new iShares Biotechnology ETF positions in Q3 2025 and 65 closed out, a net change of +20 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2025 was BNP Paribas Financial Markets, an estimated $198M added.
- The largest iShares Biotechnology ETF seller in Q3 2025 was Morgan Stanley, an estimated $67.4M sold.
Based on aggregated 13F filings for Q3 2025.